Thermo Fisher Scientific has announced that Millipore has implemented Watson Lims within its Preclinical and Clinical Development Services group.
The group will use Watson Lims in its Regulatory Compliant Laboratory in the development, validation and application of ligand binding assays that enable the production of biopharmaceuticals and translational biomarker applications.
Millipore will also use Thermo Scientific Integration Manager to provide the connectivity necessary to enable Watson Lims to be fully integrated with the laboratory's instrumentation, databases and ERP systems.
The inclusion of Thermo Scientific Designer enables a consistent reporting system for the data created and stored in the Watson database.
By installing Thermo Scientific Watson Lims, Integration Manager and Designer to connect laboratory instruments and the source of the data to the Lims and the reporting tools, Millipore has integrated its Regulatory Compliant Laboratory with the rest of the organisation.
This has enabled management to have access to critical laboratory data when they need it, in a format that will allow improved decision making.
This integration of a Thermo Scientific Lims solution with multiple laboratory instruments and a management reporting tool is an example of Thermo Scientific Connects.
Thermo Scientific Connects is a set of tools that use company products such as Lims, chromatography data system (CDS) capabilities with expertise in enterprise systems integration, all working together to improve the transfer of knowledge between laboratory-generated data and enterprise-level information systems.
Connects assists organisations in integrating application-specific workflows, thereby transforming laboratory data into relevant business information and maximising a company's enterprise system investments to better support critical management decisions in a resource-constrained environment.
Millipore's Biopharma Services organisation provides contract research services to the pharmaceutical and biotech industries through a wide range of bioanalytical services and capabilities supporting discovery, lead optimisation, ADME/Tox and Phase I-V clinical trials.
These services include bioanalysis of biotherapeutics, anti-drug antibody testing, assays for biomarkers and other specialty services.
'Watson allows us to deliver results and services for immunogenicity testing, determination of novel biomarkers and pharmacokinetic assessment of biotherapeutics,' said Craig Morley, global managing director for Millipore's Biopharma Services business.
'Integrating the Watson database with the rest of the organisation enables us to make better informed management decisions and deliver improved services to our customers,' he added.
